Back to mobile site

Neurocrine Bio. (NBIX) PT Raised to $182 at BofA Securities

December 20, 2024 12:49 PM EST Send to a Friend
BofA Securities analyst Tazeen Ahmad raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $182.00 (from $172.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login